Advertisement

Nanocarriers as Tools for Delivery of Nature Derived Compounds and Extracts with Therapeutic Activity

Chapter
Part of the Sustainable Agriculture Reviews book series (SARV, volume 44)

Abstract

Natural medicine found its use over a long period of time. These were effectively used in treating various ailments since ancient times. Initially simple extracts were used for treatment followed by isolated compounds. Natural compounds formed integral part of drug discovery programmes for most of the time. However, with the introduction of combinatorial chemistry the use of natural compounds reduced gradually, nevertheless, natural compounds were still under extensive evaluation and newer products were being approved. Many natural compounds have potential to treat various life threatening diseases for which synthetic medicine doesn’t have specific cure. However, natural compounds have limitations owing to their poor solubility, stability and permeability. This led to their reduced usage in clinical stage.

Nanocarriers due to their unique properties, offers successful delivery of various synthetic drugs by improving/modifying the properties such as solubility, pharmacokinetics and specificity. These advantages increased the interest towards development of various nanocarriers for the effective delivery of natural molecules. This chapter explores the various delivery options of different bioactive natural molecules and extracts using different nano carriers made of polymers, lipids and inorganic materials. Various natural molecules used in different disease conditions such as Alzheimer’s, diabetes, microbial infections, inflammatory condition and psoriasis were selected and their limitation in reaching clinical stage was discussed. The role of nanocarriers in overcoming these limitations and improving their clinical promise was highlighted with relevant case studies or examples.

Keywords

Nanotechnology Antibiotics Flavonoids Plant extracts Nanoparticles Liposomes 

Abbreviations

AUC

Area under the curve

EGCG

Epigallocatechin-3-gallate

NLC

Nanostructured lipid carrier

PLGA

Poly lactic-co-glycolic

References

  1. Alam N, Hossain M, Khalil MI, Moniruzzaman M, Sulaiman SA, Gan SH (2012a) Recent advances in elucidating the biological properties of Withania somnifera and its potential role in health benefits. Phytochem Rev 11(1):97–112.  https://doi.org/10.1007/s11101-011-9221-5CrossRefGoogle Scholar
  2. Alam S, Khan ZI, Mustafa G, Kumar M, Islam F, Bhatnagar A, Ahmad FJ (2012b) Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine 7:5705.  https://doi.org/10.2147/IJN.S35329PubMedCrossRefPubMedCentralGoogle Scholar
  3. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65(1):36–48.  https://doi.org/10.1016/j.addr.2012.09.037PubMedCrossRefPubMedCentralGoogle Scholar
  4. Amri A, Chaumeil J, Sfar S, Charrueau C (2012) Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 158(2):182–193.  https://doi.org/10.1016/j.jconrel.2011.09.083PubMedCrossRefPubMedCentralGoogle Scholar
  5. Amritpal S, Sanjiv D, Navpreet K, Jaswinder S (2010) Berberine: alkaloid with wide spectrum of pharmacological activities. J Nat Prod (India) 3:64–75Google Scholar
  6. Ananingsih VK, Sharma A, Zhou W (2013) Green tea catechins during food processing and storage: a review on stability and detection. Food Res Int 50(2):469–479.  https://doi.org/10.1016/j.foodres.2011.03.004CrossRefGoogle Scholar
  7. Ankola D, Wadsworth R, Ravi Kumar M (2011) Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. J Biomed Nanotechnol 7(2):300–307.  https://doi.org/10.1166/jbn.2011.1278PubMedCrossRefPubMedCentralGoogle Scholar
  8. Ansari KA, Vavia PR, Trotta F, Cavalli R (2011) Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech 12(1):279–286.  https://doi.org/10.1208/s12249-011-9584-3PubMedCrossRefPubMedCentralGoogle Scholar
  9. Antçnio E, Khalil NM, Mainardes RM (2016) Bovine serum albumin nanoparticles containing quercetin: characterization and antioxidant activity. J Nanosci Nanotechnol 16(2):1346–1353.  https://doi.org/10.1166/jnn.2016.11672CrossRefGoogle Scholar
  10. Anwar H, Dasgupta M, Lam K, Costerton JW (1989) Tobramycin resistance of mucoid Pseudomonas aeruginosa biofilm grown under iron limitation. J Antimicrob Chemother 24(5):647–655.  https://doi.org/10.1093/jac/24.5.647PubMedCrossRefPubMedCentralGoogle Scholar
  11. Avadhani KS, Manikkath J, Tiwari M, Chandrasekhar M, Godavarthi A, Vidya SM, Hariharapura RC, Kalthur G, Udupa N, Mutalik S (2017) Skin delivery of epigallocatechin-3-gallate (EGCG) and hyaluronic acid loaded nano-transfersomes for antioxidant and anti-aging effects in UV radiation induced skin damage. Drug Deliv 24(1):61–74.  https://doi.org/10.1080/10717544.2016.1228718PubMedCrossRefPubMedCentralGoogle Scholar
  12. Badary OA, Al-Shabanah OA, Nagi MN, Al-Bekairi AM, Elmazar M (1998) Acute and subchronic toxicity of thymoquinone in mice. Drug Dev Res 44(2–3):56–61.  https://doi.org/10.1002/(SICI)1098-2299(199806/07)44:2/3<56::AID-DDR2>3.0.CO;2-9CrossRefGoogle Scholar
  13. Bajwa S, Munawar A, Khan W (2017) Nanotechnology in medicine: innovation to market. Pharm Bioprocess 5(2):11–15Google Scholar
  14. Barenholz YC (2012) Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release 160(2):117–134.  https://doi.org/10.1016/j.jconrel.2012.03.020PubMedCrossRefPubMedCentralGoogle Scholar
  15. Başaran E, Demirel M, Sırmagül B, Yazan Y (2010) Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 27(1):37–47.  https://doi.org/10.3109/02652040902846883PubMedCrossRefPubMedCentralGoogle Scholar
  16. Battaglia L, D’Addino I, Peira E, Trotta M, Gallarate M (2012) Solid lipid nanoparticles prepared by coacervation method as vehicles for ocular cyclosporine. J Drug Delivery Sci Technol 22(2):125–130.  https://doi.org/10.1016/S1773-2247(12)50016-XCrossRefGoogle Scholar
  17. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5(6):493.  https://doi.org/10.1038/nrd2060PubMedCrossRefPubMedCentralGoogle Scholar
  18. Bianco A, Kostarelos K, Prato M (2005) Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 9(6):674–679.  https://doi.org/10.1016/j.cbpa.2005.10.005PubMedCrossRefPubMedCentralGoogle Scholar
  19. Bilia AR, Piazzini V, Guccione C, Risaliti L, Asprea M, Capecchi G, Bergonzi MC (2017) Improving on nature: the role of nanomedicine in the development of clinical natural drugs. Planta Med 83(05):366–381.  https://doi.org/10.1055/s-0043-102949PubMedCrossRefPubMedCentralGoogle Scholar
  20. Bittner B, Mountfield R (2002) Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Discov Devel 5(1):59–71PubMedPubMedCentralGoogle Scholar
  21. Blessy M, Patel RD, Prajapati PN, Agrawal Y (2014) Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal 4(3):159–165.  https://doi.org/10.1016/j.jpha.2013.09.003PubMedCrossRefPubMedCentralGoogle Scholar
  22. Boisseau P, Loubaton B (2011) Nanomedicine, nanotechnology in medicine. Comptes Rendus Physique 12(7):620–636.  https://doi.org/10.1016/j.crhy.2011.06.001CrossRefGoogle Scholar
  23. Bonechi C, Martini S, Ciani L, Lamponi S, Rebmann H, Rossi C, Ristori S (2012) Using liposomes as carriers for polyphenolic compounds: the case of trans-resveratrol. PLoS One 7(8):e41438.  https://doi.org/10.1371/journal.pone.0041438PubMedCrossRefPubMedCentralGoogle Scholar
  24. Borel JF, Feurer C, Gubler H, Stähelin H (1994) Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 43(3–4):179–186.  https://doi.org/10.1007/BF01986686PubMedCrossRefPubMedCentralGoogle Scholar
  25. Broach JR, Thorner J (1996) High-throughput screening for drug discovery. Nature 384(6604):14–16PubMedCrossRefGoogle Scholar
  26. Caddeo C, Teskač K, Sinico C, Kristl J (2008) Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm 363(1–2):183–191.  https://doi.org/10.1016/j.ijpharm.2008.07.024PubMedCrossRefPubMedCentralGoogle Scholar
  27. Cano A, Ettcheto M, Chang J-H, Barroso E, Espina M, Kühne BA, Barenys M, Auladell C, Folch J, Souto EB (2019) Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer’s disease mice model. J Control Release.  https://doi.org/10.1016/j.jconrel.2019.03.010
  28. Caster JM, Patel AN, Zhang T, Wang A (2017) Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(1):e1416.  https://doi.org/10.1002/wnan.1416CrossRefGoogle Scholar
  29. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238(1–2):241–245.  https://doi.org/10.1016/S0378-5173(02)00080-7PubMedCrossRefPubMedCentralGoogle Scholar
  30. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR (2003) Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 92(5):1085–1094.  https://doi.org/10.1002/jps.10368PubMedCrossRefPubMedCentralGoogle Scholar
  31. Cerchiara T, Abruzzo A, Di Cagno M, Bigucci F, Bauer-Brandl A, Parolin C, Vitali B, Gallucci M, Luppi B (2015) Chitosan based micro-and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. Eur J Pharm Biopharm 92:112–119.  https://doi.org/10.1016/j.ejpb.2015.03.004PubMedCrossRefPubMedCentralGoogle Scholar
  32. Chan LM, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21(1):25–51.  https://doi.org/10.1016/j.ejps.2003.07.003PubMedCrossRefPubMedCentralGoogle Scholar
  33. Chauhan MK, Bhatt N (2019) Bioavailability enhancement of polymyxin B with novel drug delivery: development and optimization using quality-by-design approach. J Pharm Sci 108(4):1521–1528.  https://doi.org/10.1016/j.xphs.2018.11.032PubMedCrossRefPubMedCentralGoogle Scholar
  34. Chinembiri TN, Gerber M, Du Plessis LH, Du Preez JL, Hamman JH, Du Plessis J (2017) Topical delivery of Withania somnifera crude extracts in niosomes and solid lipid nanoparticles. Pharmacogn Mag 13(Suppl 3):S663.  https://doi.org/10.4103/pm.pm_489_16PubMedCrossRefPubMedCentralGoogle Scholar
  35. Cohen B (1998) Amphotericin B toxicity and lethality: a tale of two channels. Int J Pharm 162(1–2):95–106.  https://doi.org/10.1016/S0378-5173(97)00417-1CrossRefGoogle Scholar
  36. Cragg GM (1998) Paclitaxel (Taxol®): a success story with valuable lessons for natural product drug discovery and development. Med Res Rev 18(5):315–331.  https://doi.org/10.1002/(SICI)1098-1128(199809)18:5<315::AID-MED3>3.0.CO;2-WPubMedCrossRefPubMedCentralGoogle Scholar
  37. Crowley P, Martini LG (2001) Drug-excipient interactions. Pharm Technol 4:7–12Google Scholar
  38. da Rocha Lindner G, Bonfanti Santos D, Colle D, Gasnhar Moreira EL, Daniel Prediger R, Farina M, Khalil NM, Mara Mainardes R (2015) Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly (lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine 10(7):1127–1138.  https://doi.org/10.2217/nnm.14.165PubMedCrossRefPubMedCentralGoogle Scholar
  39. Dag D, Oztop MH (2017) Formation and characterization of green tea extract loaded liposomes. J Food Sci 82(2):463–470.  https://doi.org/10.1111/1750-3841.13615PubMedCrossRefPubMedCentralGoogle Scholar
  40. Dai J, Nagai T, Wang X, Zhang T, Meng M, Zhang Q (2004) pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm 280(1–2):229–240.  https://doi.org/10.1016/j.ijpharm.2004.05.006PubMedCrossRefPubMedCentralGoogle Scholar
  41. Damle M, Mallya R (2016) Development and evaluation of a novel delivery system containing phytophospholipid complex for skin aging. AAPS PharmSciTech 17(3):607–617.  https://doi.org/10.1208/s12249-015-0386-xPubMedCrossRefPubMedCentralGoogle Scholar
  42. Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74(3):417–433.  https://doi.org/10.1128/MMBR.00016-10PubMedCrossRefPubMedCentralGoogle Scholar
  43. de Carvalho RF, Ribeiro IF, Miranda-Vilela AL, de Souza Filho J, Martins OP, e Silva DOC, Tedesco AC, Lacava ZGM, Báo SN, Sampaio RNR (2013) Leishmanicidal activity of amphotericin B encapsulated in PLGA–DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. Exp Parasitol 135(2):217–222.  https://doi.org/10.1016/j.exppara.2013.07.008PubMedCrossRefPubMedCentralGoogle Scholar
  44. Delmas D, Aires V, Limagne E, Dutartre P, Mazué F, Ghiringhelli F, Latruffe N (2011) Transport, stability, and biological activity of resveratrol. Ann N Y Acad Sci 1215(1):48–59.  https://doi.org/10.1111/j.1749-6632.2010.05871.xPubMedCrossRefPubMedCentralGoogle Scholar
  45. Devi VK, Jain N, Valli KS (2010) Importance of novel drug delivery systems in herbal medicines. Pharmacogn Rev 4(7):27.  https://doi.org/10.4103/0973-7847.65322PubMedCrossRefPubMedCentralGoogle Scholar
  46. Dhawan S, Kapil R, Singh B (2011) Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 63(3):342–351.  https://doi.org/10.1111/j.2042-7158.2010.01225.xPubMedCrossRefPubMedCentralGoogle Scholar
  47. Dias DA, Urban S, Roessner U (2012) A historical overview of natural products in drug discovery. Meta 2(2):303–336.  https://doi.org/10.3390/metabo2020303CrossRefGoogle Scholar
  48. Dube A, Nicolazzo JA, Larson I (2010) Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (−)-epigallocatechin gallate. Eur J Pharm Sci 41(2):219–225.  https://doi.org/10.1016/j.ejps.2010.06.010PubMedCrossRefPubMedCentralGoogle Scholar
  49. Dube A, Nicolazzo JA, Larson I (2011) Chitosan nanoparticles enhance the plasma exposure of (−)-epigallocatechin gallate in mice through an enhancement in intestinal stability. Eur J Pharm Sci 44(3):422–426.  https://doi.org/10.1016/j.ejps.2011.09.004PubMedCrossRefPubMedCentralGoogle Scholar
  50. Dupont B (2002) Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 49(1):31–36.  https://doi.org/10.1093/jac/49.suppl_1.31PubMedCrossRefPubMedCentralGoogle Scholar
  51. Dwivedi P, Khatik R, Khandelwal K, Taneja I, Raju KSR, Paliwal SK, Dwivedi AK, Mishra PR (2014) Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm 466(1–2):321–327.  https://doi.org/10.1016/j.ijpharm.2014.03.036PubMedCrossRefPubMedCentralGoogle Scholar
  52. Efferth T, Bilia A, Osman A, Elsohly M, Wink M, Bauer R, Khan I, Bergonzi M, Marin J (2016) Expanding the therapeutic spectrum of artemisinin: activity against infectious diseases beyond malaria and novel pharmaceutical developments. World J Tradit Chin Med 2:1–23.  https://doi.org/10.15806/j.issn.2311-8571.2016.0002CrossRefGoogle Scholar
  53. Egbaria K, Ramachandran C, Weiner N (1990) Topical delivery of ciclosporin: evaluation of various formulations using in vitro diffusion studies in hairless mouse skin. Skin Pharmacol Physiol 3(1):21–28.  https://doi.org/10.1159/000210837CrossRefGoogle Scholar
  54. Ellis D (2002) Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49(1):7–10.  https://doi.org/10.1093/jac/49.suppl_1.7PubMedCrossRefPubMedCentralGoogle Scholar
  55. Erlund I (2004) Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 24(10):851–874.  https://doi.org/10.1016/j.nutres.2004.07.005CrossRefGoogle Scholar
  56. Esmaeili A, Rafiee R (2015) Preparation and biological activity of nanocapsulated Glycyrrhiza glabra L. var. glabra. Flavour Fragr J 30(1):113–119.  https://doi.org/10.1002/ffj.3225CrossRefGoogle Scholar
  57. Fang J-Y, Hwang T-L, Huang Y-L, Fang C-L (2006) Enhancement of the transdermal delivery of catechins by liposomes incorporating anionic surfactants and ethanol. Int J Pharm 310(1–2):131–138.  https://doi.org/10.1016/j.ijpharm.2005.12.004PubMedCrossRefPubMedCentralGoogle Scholar
  58. Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR (2018) Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine 14(1):93–126.  https://doi.org/10.2217/nnm-2018-0120PubMedCrossRefPubMedCentralGoogle Scholar
  59. Felgines C, Texier O, Morand C, Manach C, Scalbert A, Régerat F, Rémésy C (2000) Bioavailability of the flavanone naringenin and its glycosides in rats. Am J Physiol Gastrointest Liver Physiol 279(6):G1148–G1154.  https://doi.org/10.1152/ajpgi.2000.279.6.G1148PubMedCrossRefPubMedCentralGoogle Scholar
  60. Fernández L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock RE (2010) Adaptive resistance to the “last hope” antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob Agents Chemother 54(8):3372–3382.  https://doi.org/10.1128/AAC.00242-10PubMedCrossRefPubMedCentralGoogle Scholar
  61. Formica J, Regelson W (1995) Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 33(12):1061–1080.  https://doi.org/10.1016/0278-6915(95)00077-1PubMedCrossRefPubMedCentralGoogle Scholar
  62. Francioso A, Mastromarino P, Masci A, d’Erme M, Mosca L (2014) Chemistry, stability and bioavailability of resveratrol. Med Chem 10(3):237–245PubMedCrossRefGoogle Scholar
  63. Freitas RA Jr (2005) What is nanomedicine? Nanomedicine 1(1):2–9.  https://doi.org/10.1016/j.nano.2004.11.003PubMedCrossRefPubMedCentralGoogle Scholar
  64. Frémont L (2000) Biological effects of resveratrol. Life Sci 66(8):663–673.  https://doi.org/10.1016/S0024-3205(99)00410-5PubMedCrossRefPubMedCentralGoogle Scholar
  65. Fröhlich T, Hahn F, Belmudes L, Leidenberger M, Friedrich O, Kappes B, Couté Y, Marschall M, Tsogoeva SB (2018) Synthesis of artemisinin-derived dimers, trimers and dendrimers: investigation of their antimalarial and antiviral activities including putative mechanisms of action. Chem Eur J 24(32):8103–8113.  https://doi.org/10.1002/chem.201800729PubMedCrossRefPubMedCentralGoogle Scholar
  66. Gauttam VK, Kalia AN (2013) Development of polyherbal antidiabetic formulation encapsulated in the phospholipids vesicle system. J Adv Pharm Technol Res 4(2):108.  https://doi.org/10.4103/2231-4040.111527PubMedCrossRefPubMedCentralGoogle Scholar
  67. Ghalioungui P (1987) The Ebers papyrus: a new English translation, commentaries and glossaries. Academy of Scientific Research and Technology, CairoGoogle Scholar
  68. Gharib A, Faezizadeh Z, Godarzee M (2013) Therapeutic efficacy of epigallocatechin gallate-loaded nanoliposomes against burn wound infection by methicillin-resistant Staphylococcus aureus. Skin Pharmacol Physiol 26(2):68–75.  https://doi.org/10.1159/000345761PubMedCrossRefPubMedCentralGoogle Scholar
  69. Gholamnezhad Z, Havakhah S, Boskabady MH (2016) Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: a review. J Ethnopharmacol 190:372–386.  https://doi.org/10.1016/j.jep.2016.06.061PubMedCrossRefPubMedCentralGoogle Scholar
  70. Gillies ER, Frechet JM (2005) Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 10(1):35–43.  https://doi.org/10.1016/S1359-6446(04)03276-3PubMedCrossRefPubMedCentralGoogle Scholar
  71. Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Güneri T, Caramella C (2008) Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 364(1):76–86.  https://doi.org/10.1016/j.ijpharm.2008.07.028PubMedCrossRefPubMedCentralGoogle Scholar
  72. Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O (2012) Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomedicine 7:1841.  https://doi.org/10.2147/IJN.S29710PubMedCrossRefPubMedCentralGoogle Scholar
  73. Gopi S, Amalraj A, Haponiuk JT, Thomas S (2016) Introduction of nanotechnology in herbal drugs and nutraceutical: a review. J Nanomedicine Biotherapeutic Discov 6(2):1–8.  https://doi.org/10.4172/2155-983X.1000143CrossRefGoogle Scholar
  74. Group IEW ICH guideline Q1A (R2) stability testing of new drug substances and products. In: International Conference on Harmonization, 2003. vol 24. snGoogle Scholar
  75. Gu H, Ho P, Tong E, Wang L, Xu B (2003) Presenting vancomycin on nanoparticles to enhance antimicrobial activities. Nano Lett 3(9):1261–1263.  https://doi.org/10.1021/nl034396zCrossRefGoogle Scholar
  76. Gupta L, Sharma AK, Gothwal A, Khan MS, Khinchi MP, Qayum A, Singh SK, Gupta U (2017) Dendrimer encapsulated and conjugated delivery of berberine: a novel approach mitigating toxicity and improving in vivo pharmacokinetics. Int J Pharm 528(1–2):88–99.  https://doi.org/10.1016/j.ijpharm.2017.04.073PubMedCrossRefPubMedCentralGoogle Scholar
  77. Haddadi A, Elamanchili P, Lavasanifar A, Das S, Shapiro J, Samuel J (2008) Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J Biomed Mater Res A 84(4):885–898.  https://doi.org/10.1002/jbm.a.31373PubMedCrossRefPubMedCentralGoogle Scholar
  78. Haghighi P, Ghaffari S, Arbabi Bidgoli S, Qomi M, Haghighat S (2018) Preparation, characterization and evaluation of Ginkgo biloba solid lipid nanoparticles. Nanomedicine Res J 3(2):71–78.  https://doi.org/10.22034/nmrj.2018.02.003CrossRefGoogle Scholar
  79. Hansch C, Clayton JM (1973) Lipophilic character and biological activity of drugs II: the parabolic case. J Pharm Sci 62(1):1–21.  https://doi.org/10.1002/jps.2600620102PubMedCrossRefPubMedCentralGoogle Scholar
  80. Harvey AL (2008) Natural products in drug discovery. Drug Discov Today 13(19–20):894–901.  https://doi.org/10.1016/j.drudis.2008.07.004PubMedCrossRefPubMedCentralGoogle Scholar
  81. Hiemenz JW, Walsh TJ (1996) Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 22(Supplement_2):S133–S144.  https://doi.org/10.1093/clinids/22.Supplement_2.S133PubMedCrossRefPubMedCentralGoogle Scholar
  82. Hillaireau H, Couvreur P (2009) Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66(17):2873–2896.  https://doi.org/10.1007/s00018-009-0053-zPubMedCrossRefPubMedCentralGoogle Scholar
  83. Hsu Chen CC, Feingold DS (1973) Mechanism of polymyxin B action and selectivity toward biologic membranes. Biochemistry 12(11):2105–2111.  https://doi.org/10.1021/bi00735a014CrossRefGoogle Scholar
  84. Huyck TK, Gradishar W, Manuguid F, Kirkpatrick P (2011) Eribulin mesylate. Nature Publishing GroupGoogle Scholar
  85. Ibrahim N, Ibrahim H, Sabater AM, Mazier D, Valentin A, Nepveu F (2015) Artemisinin nanoformulation suitable for intravenous injection: preparation, characterization and antimalarial activities. Int J Pharm 495(2):671–679.  https://doi.org/10.1016/j.ijpharm.2015.09.020PubMedCrossRefPubMedCentralGoogle Scholar
  86. Imanshahidi M, Hosseinzadeh H (2008) Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 22(8):999–1012.  https://doi.org/10.1002/ptr.2399PubMedCrossRefPubMedCentralGoogle Scholar
  87. Insua I, Zizmare L, Peacock AF, Krachler AM, Fernandez-Trillo F (2017) Polymyxin B containing polyion complex (PIC) nanoparticles: improving the antimicrobial activity by tailoring the degree of polymerisation of the inert component. Sci Rep 7(1):9396.  https://doi.org/10.1038/s41598-017-09667-3PubMedCrossRefPubMedCentralGoogle Scholar
  88. Isacchi B, Arrigucci S, Gl M, Bergonzi MC, Vannucchi MG, Novelli A, Bilia AR (2011) Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. J Liposome Res 21(3):237–244.  https://doi.org/10.3109/08982104.2010.539185PubMedCrossRefPubMedCentralGoogle Scholar
  89. Ismailos G, Reppas C, Dressman JB, Macheras P (1991) Unusual solubility behaviour of cyclosporin A in aqueous media. J Pharm Pharmacol 43(4):287–289.  https://doi.org/10.1111/j.2042-7158.1991.tb06688.xPubMedCrossRefPubMedCentralGoogle Scholar
  90. Italia J, Datta P, Ankola D, Kumar M (2008) Nanoparticles enhance per oral bioavailability of poorly available molecules: epigallocatechin gallate nanoparticles ameliorates cyclosporine induced nephrotoxicity in rats at three times lower dose than oral solution. J Biomed Nanotechnol 4(3):304–312.  https://doi.org/10.1166/jbn.2008.341CrossRefGoogle Scholar
  91. Iyer AK, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11(17–18):812–818.  https://doi.org/10.1016/j.drudis.2006.07.005PubMedCrossRefPubMedCentralGoogle Scholar
  92. Jain A, Pooladanda V, Bulbake U, Doppalapudi S, Rafeeqi TA, Godugu C, Khan W (2017) Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis. Nanomedicine 13(7):2251–2262.  https://doi.org/10.1016/j.nano.2017.06.009PubMedCrossRefPubMedCentralGoogle Scholar
  93. Ji P, Yu T, Liu Y, Jiang J, Xu J, Zhao Y, Hao Y, Qiu Y, Zhao W, Wu C (2016) Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. Drug Des Devel Ther 10:911.  https://doi.org/10.2147/DDDT.S97738PubMedCrossRefPubMedCentralGoogle Scholar
  94. Joshi M, Pathak S, Sharma S, Patravale V (2008) Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: nanoject. Int J Pharm 364(1):119–126.  https://doi.org/10.1016/j.ijpharm.2008.07.032PubMedCrossRefPubMedCentralGoogle Scholar
  95. Jung YD, Ellis LM (2001) Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp Pathol 82(6):309–316.  https://doi.org/10.1046/j.1365-2613.2001.00205.xPubMedCrossRefPubMedCentralGoogle Scholar
  96. Kakran M, Sahoo NG, Li L, Judeh Z (2010) Dissolution of artemisinin/polymer composite nanoparticles fabricated by evaporative precipitation of nanosuspension. J Pharm Pharmacol 62(4):413–421.  https://doi.org/10.1211/jpp.62.04.0002PubMedCrossRefPubMedCentralGoogle Scholar
  97. Kakran M, Sahoo N, Li L (2011) Dissolution enhancement of quercetin through nanofabrication, complexation, and solid dispersion. Colloids Surf B: Biointerfaces 88(1):121–130.  https://doi.org/10.1016/j.colsurfb.2011.06.020PubMedCrossRefPubMedCentralGoogle Scholar
  98. Kakran M, Sahoo NG, Li L, Judeh Z (2012) Fabrication of quercetin nanoparticles by anti-solvent precipitation method for enhanced dissolution. Powder Technol 223:59–64.  https://doi.org/10.1016/j.powtec.2011.08.021CrossRefGoogle Scholar
  99. Kaur H, Kumar B, Chakrabarti A, Medhi B, Modi M, Radotra BD, Aggarwal R, Sinha VR (2019) A new therapeutic approach for brain delivery of epigallocatechin gallate: development and characterization studies. Curr Drug Deliv 16(1):59–65.  https://doi.org/10.2174/1567201815666180926121104PubMedCrossRefPubMedCentralGoogle Scholar
  100. Kausar H, Mujeeb M, Ahad A, Moolakkadath T, Aqil M, Ahmad A, Akhter MH (2019) Optimization of ethosomes for topical thymoquinone delivery for the treatment of skin acne. J Drug Delivery Sci Technol 49:177–187.  https://doi.org/10.1016/j.jddst.2018.11.016CrossRefGoogle Scholar
  101. Keck CM, Müller RH (2006) Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62(1):3–16.  https://doi.org/10.1016/j.ejpb.2005.05.009PubMedCrossRefPubMedCentralGoogle Scholar
  102. Khan W, Farah S, Nyska A, Domb AJ (2013) Carrier free rapamycin loaded drug eluting stent: in vitro and in vivo evaluation. J Control Release 168(1):70–76.  https://doi.org/10.1016/j.jconrel.2013.02.012PubMedCrossRefPubMedCentralGoogle Scholar
  103. Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J (2015) Self-nanoemulsifying drug delivery system (SNEDDS) of the poorly water-soluble grapefruit flavonoid Naringenin: design, characterization, in vitro and in vivo evaluation. Drug Deliv 22(4):552–561.  https://doi.org/10.3109/10717544.2013.878003PubMedCrossRefPubMedCentralGoogle Scholar
  104. Kleijnen J, Knipschild P (1992) Ginkgo biloba. Lancet 340(8828):1136–1139.  https://doi.org/10.1016/0140-6736(92)93158-JPubMedCrossRefPubMedCentralGoogle Scholar
  105. Klockgether-Radke A (2002) FW Sertürner and the discovery of morphine. 200 years of pain therapy with opioids. Anästhesiol Intensivmed Notfallmed Schmerzther 37(5):244–249PubMedCrossRefGoogle Scholar
  106. Kobierski S, Ofori-Kwakye K, Müller R, Keck C (2009) Resveratrol nanosuspensions for dermal application–production, characterization, and physical stability. Die Pharmazie Int J Pharm Sci 64(11):741–747.  https://doi.org/10.1691/ph.2009.9097CrossRefGoogle Scholar
  107. Krishna S, Bustamante L, Haynes RK, Staines HM (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29(10):520–527.  https://doi.org/10.1016/j.tips.2008.07.004PubMedCrossRefPubMedCentralGoogle Scholar
  108. Kumar RP, Abraham A (2016) PVP-coated naringenin nanoparticles for biomedical applications–in vivo toxicological evaluations. Chem Biol Interact 257:110–118.  https://doi.org/10.1016/j.cbi.2016.07.012PubMedCrossRefPubMedCentralGoogle Scholar
  109. Kumar R, Dogra S, Amarji B, Singh B, Kumar S, Vinay K, Mahajan R, Katare O (2016) Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: a randomized clinical trial. JAMA Dermatol 152(7):807–815.  https://doi.org/10.1001/jamadermatol.2016.0859PubMedCrossRefPubMedCentralGoogle Scholar
  110. Kumari A, Yadav SK, Pakade YB, Singh B, Yadav SC (2010) Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf B: Biointerfaces 80(2):184–192.  https://doi.org/10.1016/j.colsurfb.2010.06.002PubMedCrossRefPubMedCentralGoogle Scholar
  111. Laniado-Laborín R, Cabrales-Vargas MN (2009) Amphotericin B: side effects and toxicity. Rev Iberoam Micol 26(4):223–227.  https://doi.org/10.1016/j.riam.2009.06.003PubMedCrossRefGoogle Scholar
  112. Lapenna S, Bilia AR, Morris GA, Nilsson M (2009) Novel artemisinin and curcumin micellar formulations: drug solubility studies by NMR spectroscopy. J Pharm Sci 98(10):3666–3675.  https://doi.org/10.1002/jps.21685PubMedCrossRefPubMedCentralGoogle Scholar
  113. Levine DP (2006) Vancomycin: a history. Clin Infect Dis 42(Supplement_1):S5–S12.  https://doi.org/10.1086/491709PubMedCrossRefGoogle Scholar
  114. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133(3):238–244.  https://doi.org/10.1016/j.jconrel.2008.10.002PubMedCrossRefPubMedCentralGoogle Scholar
  115. Li J, Kim SG, Blenis J (2014) Rapamycin: one drug, many effects. Cell Metab 19(3):373–379.  https://doi.org/10.1016/j.cmet.2014.01.001PubMedCrossRefPubMedCentralGoogle Scholar
  116. Lin Y-H, Lin J-H, Chou S-C, Chang S-J, Chung C-C, Chen Y-S, Chang C-H (2015) Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study. Nanomedicine 10(1):57–71.  https://doi.org/10.2217/nnm.14.76PubMedCrossRefGoogle Scholar
  117. Liu Y, Feng N (2015) Nanocarriers for the delivery of active ingredients and fractions extracted from natural products used in traditional Chinese medicine (TCM). Adv Colloid Interf Sci 221:60–76.  https://doi.org/10.1016/j.cis.2015.04.006CrossRefGoogle Scholar
  118. Logothetidis S (2006) Nanotechnology in medicine: the medicine of tomorrow and nanomedicine. Hippokratia 10(1):7–21Google Scholar
  119. Loureiro J, Andrade S, Duarte A, Neves A, Queiroz J, Nunes C, Sevin E, Fenart L, Gosselet F, Coelho M (2017) Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease. Molecules 22(2):277.  https://doi.org/10.3390/molecules22020277CrossRefGoogle Scholar
  120. Lu H, Meng X, Li C, Sang S, Patten C, Sheng S, Hong J, Bai N, Winnik B, Ho C-T (2003) Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab Dispos 31(4):452–461.  https://doi.org/10.1124/dmd.31.4.452PubMedCrossRefPubMedCentralGoogle Scholar
  121. Lu Q, Li D-C, Jiang J-G (2011) Preparation of a tea polyphenol nanoliposome system and its physicochemical properties. J Agric Food Chem 59(24):13004–13011.  https://doi.org/10.1021/jf203194wPubMedCrossRefPubMedCentralGoogle Scholar
  122. Lutsenko SV, Gromovykh TI, Krasnyuk II, Vasilenko IA, Feldman NB (2018) Antihepatotoxic activity of liposomal silibinin. BioNanoScience 8(2):581–586.  https://doi.org/10.1007/s12668-018-0512-9CrossRefGoogle Scholar
  123. Maas J, Kamm W, Hauck G (2007) An integrated early formulation strategy–from hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm 66(1):1–10.  https://doi.org/10.1016/j.ejpb.2006.09.011PubMedCrossRefPubMedCentralGoogle Scholar
  124. Mabberley D (2008) Mabberlev’s plant-book. Cambridge University Press, CambridgeGoogle Scholar
  125. Maity S, Mukhopadhyay P, Kundu PP, Chakraborti AS (2017) Alginate coated chitosan core-shell nanoparticles for efficient oral delivery of naringenin in diabetic animals—an in vitro and in vivo approach. Carbohydr Polym 170:124–132.  https://doi.org/10.1016/j.carbpol.2017.04.066PubMedCrossRefPubMedCentralGoogle Scholar
  126. Mandel S, Weinreb O, Amit T, Youdim MB (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (−)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem 88(6):1555–1569.  https://doi.org/10.1046/j.1471-4159.2003.02291.xPubMedCrossRefPubMedCentralGoogle Scholar
  127. Manea A-M, Andronescu C, Meghea A (2014) Green tea extract loaded into solid lipid nanoparticles. UPB Sci Bull B Chem Mater Sci 76(2):125–136Google Scholar
  128. Marchiori MCL, Rigon C, Camponogara C, Oliveira SM, Cruz L (2017) Hydrogel containing silibinin-loaded pomegranate oil based nanocapsules exhibits anti-inflammatory effects on skin damage UVB radiation-induced in mice. J Photochem Photobiol B Biol 170:25–32.  https://doi.org/10.1016/j.jphotobiol.2017.03.015CrossRefGoogle Scholar
  129. Masimirembwa CM, Bredberg U, Andersson TB (2003) Metabolic stability for drug discovery and development. Clin Pharmacokinet 42(6):515–528.  https://doi.org/10.2165/00003088-200342060-00002PubMedCrossRefPubMedCentralGoogle Scholar
  130. McBain SC, Yiu HH, Dobson J (2008) Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 3(2):169PubMedPubMedCentralGoogle Scholar
  131. Mehra M, Sheorain J, Kumari S (2016) Synthesis of berberine loaded polymeric nanoparticles by central composite design. In: AIP Conference Proceedings, vol 1724. AIP Publishing, p 020060Google Scholar
  132. Mehrizi TZ, Ardestani MS, Molla Hoseini MH, Khamesipour A, Mosaffa N, Ramezani A (2018) Novel nano-sized chitosan amphotericin B formulation with considerable improvement against Leishmania major. Nanomedicine 13(24):3129–3147.  https://doi.org/10.2217/nnm-2018-0063PubMedCrossRefGoogle Scholar
  133. Merisko-Liversidge EM, Liversidge GG (2008) Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol 36(1):43–48.  https://doi.org/10.1177/0192623307310946PubMedCrossRefGoogle Scholar
  134. Messiaen A-S, Forier K, Nelis H, Braeckmans K, Coenye T (2013) Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms. PLoS One 8(11):e79220.  https://doi.org/10.1371/journal.pone.0079220PubMedCrossRefPubMedCentralGoogle Scholar
  135. Mishra L-C, Singh BB, Dagenais S (2000) Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 5(4):334–346PubMedGoogle Scholar
  136. Mout R, Moyano DF, Rana S, Rotello VM (2012) Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev 41(7):2539–2544.  https://doi.org/10.1039/C2CS15294KPubMedCrossRefPubMedCentralGoogle Scholar
  137. Müller R, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto E (2006) Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm 317(1):82–89.  https://doi.org/10.1016/j.ijpharm.2006.02.045PubMedCrossRefGoogle Scholar
  138. Musa SH, Basri M, Masoumi HRF, Shamsudin N, Salim N (2017) Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action. Int J Nanomedicine 12:2427.  https://doi.org/10.2147/IJN.S125302PubMedCrossRefPubMedCentralGoogle Scholar
  139. Naik SR, Panda VS (2007) Antioxidant and hepatoprotective effects of Ginkgo biloba phytosomes in carbon tetrachloride-induced liver injury in rodents. Liver Int 27(3):393–399.  https://doi.org/10.1111/j.1478-3231.2007.01463.xPubMedCrossRefGoogle Scholar
  140. Nallamuthu I, Parthasarathi A, Khanum F (2013) Thymoquinone-loaded PLGA nanoparticles: antioxidant and anti-microbial properties. Int Curr Pharm J 2(12):202–207.  https://doi.org/10.3329/icpj.v2i12.17017CrossRefGoogle Scholar
  141. Neog MK, Sultana F, Rasool M (2018) Targeting RAW 264.7 macrophages (M1 type) with Withaferin-A decorated mannosylated liposomes induces repolarization via downregulation of NF-κB and controlled elevation of STAT-3. Int Immunopharmacol 61:64–73.  https://doi.org/10.1016/j.intimp.2018.05.019PubMedCrossRefGoogle Scholar
  142. Neu HC (1976) Tobramycin: an overview. J Infect Dis 134:S3–S19PubMedCrossRefGoogle Scholar
  143. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S (2014) Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv 11(8):1285–1298.  https://doi.org/10.1517/17425247.2014.919253PubMedCrossRefGoogle Scholar
  144. Pardeike J, Hommoss A, Müller RH (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366(1–2):170–184.  https://doi.org/10.1016/j.ijpharm.2008.10.003PubMedCrossRefGoogle Scholar
  145. Park S, Chibli H, Wong J, Nadeau JL (2011) Antimicrobial activity and cellular toxicity of nanoparticle–polymyxin B conjugates. Nanotechnology 22(18):185101.  https://doi.org/10.1088/0957-4484/22/18/185101PubMedCrossRefPubMedCentralGoogle Scholar
  146. Patwardhan B, Warude D, Pushpangadan P, Bhatt N (2005) Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med 2(4):465–473.  https://doi.org/10.1093/ecam/neh140PubMedCrossRefPubMedCentralGoogle Scholar
  147. Pelgrift RY, Friedman AJ (2013) Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev 65(13–14):1803–1815.  https://doi.org/10.1016/j.addr.2013.07.011PubMedCrossRefGoogle Scholar
  148. Portman R, Meier-Kriesche H, Swinford R, Brannan P, Kahan B (2000) Reduced variability of Neoral pharmacokinetic studies in pediatric renal transplantation. Pediatr Nephrol 15(1–2):2–6.  https://doi.org/10.1007/s004670000435PubMedCrossRefGoogle Scholar
  149. Puigdemont A, Brazís P, Ordeix L, Dalmau A, Fuertes E, Olivar A, Pérez C, Ravera I (2013) Efficacy of a new topical cyclosporine A formulation in the treatment of atopic dermatitis in dogs. Vet J 197(2):280–285.  https://doi.org/10.1016/j.tvjl.2013.02.018PubMedCrossRefGoogle Scholar
  150. Pujara N, Jambhrunkar S, Wong KY, McGuckin M, Popat A (2017) Enhanced colloidal stability, solubility and rapid dissolution of resveratrol by nanocomplexation with soy protein isolate. J Colloid Interface Sci 488:303–308.  https://doi.org/10.1016/j.jcis.2016.11.015PubMedCrossRefGoogle Scholar
  151. Qi L, Gao X (2008) Emerging application of quantum dots for drug delivery and therapy. Expert Opin Drug Deliv 5(3):263–267.  https://doi.org/10.1517/17425247.5.3.263PubMedCrossRefGoogle Scholar
  152. Rani R, Dahiya S, Dhingra D, Dilbaghi N, Kim K-H, Kumar S (2017) Evaluation of anti-diabetic activity of glycyrrhizin-loaded nanoparticles in nicotinamide-streptozotocin-induced diabetic rats. Eur J Pharm Sci 106:220–230.  https://doi.org/10.1016/j.ejps.2017.05.068PubMedCrossRefGoogle Scholar
  153. Ripoli M, Angelico R, Sacco P, Ceglie A, Mangia A (2016) Phytoliposome-based silibinin delivery system as a promising strategy to prevent hepatitis C virus infection. J Biomed Nanotechnol 12(4):770–780.  https://doi.org/10.1166/jbn.2016.2161PubMedCrossRefGoogle Scholar
  154. Roque L, Duarte N, Bronze MR, Garcia C, Alopaeus J, Molpeceres J, Hagesaether E, Tho I, Rijo P, Reis C (2018) Development of a bioadhesive nanoformulation with Glycyrrhiza glabra L. extract against Candida albicans. Biofouling 34(8):880–892.  https://doi.org/10.1080/08927014.2018.1514391PubMedCrossRefGoogle Scholar
  155. Rushmi ZT, Akter N, Mow RJ, Afroz M, Kazi M, de Matas M, Rahman M, Shariare MH (2017) The impact of formulation attributes and process parameters on black seed oil loaded liposomes and their performance in animal models of analgesia. Saudi Pharm J 25(3):404–412.  https://doi.org/10.1016/j.jsps.2016.09.011PubMedCrossRefGoogle Scholar
  156. Sahibzada MUK, Sadiq A, Faidah HS, Khurram M, Amin MU, Haseeb A, Kakar M (2018) Berberine nanoparticles with enhanced in vitro bioavailability: characterization and antimicrobial activity. Drug Des Devel Ther 12:303.  https://doi.org/10.2147/DDDT.S156123PubMedCrossRefPubMedCentralGoogle Scholar
  157. Sahoo N, Kakran M, Shaal L, Li L, Müller R, Pal M, Tan L (2011) Preparation and characterization of quercetin nanocrystals. J Pharm Sci 100(6):2379–2390.  https://doi.org/10.1002/jps.22446PubMedCrossRefGoogle Scholar
  158. Salmani J, Asghar S, Lv H, Zhou J (2014) Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. Molecules 19(5):5925–5939.  https://doi.org/10.3390/molecules19055925PubMedCrossRefPubMedCentralGoogle Scholar
  159. Santos AC, Veiga F, Ribeiro AJ (2011) New delivery systems to improve the bioavailability of resveratrol. Expert Opin Drug Deliv 8(8):973–990.  https://doi.org/10.1517/17425247.2011.581655PubMedCrossRefGoogle Scholar
  160. Seil JT, Webster TJ (2012) Antimicrobial applications of nanotechnology: methods and literature. Int J Nanomedicine 7:2767.  https://doi.org/10.2147/IJN.S24805PubMedCrossRefPubMedCentralGoogle Scholar
  161. Severino P, Chaud MV, Shimojo A, Antonini D, Lancelloti M, Santana MHA, Souto EB (2015) Sodium alginate-cross-linked polymyxin B sulphate-loaded solid lipid nanoparticles: antibiotic resistance tests and HaCat and NIH/3T3 cell viability studies. Colloids Surf B: Biointerfaces 129:191–197.  https://doi.org/10.1016/j.colsurfb.2015.03.049PubMedCrossRefGoogle Scholar
  162. Sharma P, Garg S (2010) Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 62(4–5):491–502.  https://doi.org/10.1016/j.addr.2009.11.019PubMedCrossRefPubMedCentralGoogle Scholar
  163. Shetty PK, Manikkath J, Tupally K, Kokil G, Hegde AR, Raut SY, Parekh HS, Mutalik S (2017) Skin delivery of EGCG and silibinin: potential of peptide dendrimers for enhanced skin permeation and deposition. AAPS PharmSciTech 18(6):2346–2357.  https://doi.org/10.1208/s12249-017-0718-0PubMedCrossRefGoogle Scholar
  164. Shibata S (2000) A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 120(10):849–862.  https://doi.org/10.1248/yakushi1947.120.10_849CrossRefGoogle Scholar
  165. Shoeb M (2006) Anti-cancer agents from medicinal plants. Bangladesh J Pharmacol 1(2):35–41.  https://doi.org/10.3329/bjp.v1i2.486CrossRefGoogle Scholar
  166. Siddiqui AA, Iram F, Siddiqui S, Sahu K (2014) Role of natural products in drug discovery process. Int J Drug Dev Res 6(2):172–204Google Scholar
  167. Simamora P, Alvarez JM, Yalkowsky SH (2001) Solubilization of rapamycin. Int J Pharm 213(1–2):25–29.  https://doi.org/10.1016/S0378-5173(00)00617-7PubMedCrossRefGoogle Scholar
  168. Singh G, Pai RS (2014) Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential. Expert Opin Drug Deliv 11(5):647–659.  https://doi.org/10.1517/17425247.2014.890588PubMedCrossRefGoogle Scholar
  169. Singh A, Ahmad I, Akhter S, Jain GK, Iqbal Z, Talegaonkar S, Ahmad FJ (2013) Nanocarrier based formulation of Thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies. Colloids Surf B: Biointerfaces 102:822–832.  https://doi.org/10.1016/j.colsurfb.2012.08.038PubMedCrossRefGoogle Scholar
  170. Slowing II, Vivero-Escoto JL, Wu C-W, Lin VS-Y (2008) Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60(11):1278–1288.  https://doi.org/10.1016/j.addr.2008.03.012PubMedCrossRefGoogle Scholar
  171. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E (1999) Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340(7):493–501.  https://doi.org/10.1056/NEJM199902183400701PubMedCrossRefGoogle Scholar
  172. Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD (2010) Nanolipidic particles improve the bioavailability and α-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer’s disease. Int J Pharm 389(1–2):207–212.  https://doi.org/10.1016/j.ijpharm.2010.01.012PubMedCrossRefPubMedCentralGoogle Scholar
  173. Song Y, Ping Q, Wu Z (2005) Preparation of silybin nanoemulsion and its pharmacokinetics in rabbits. J China Pharm Univ 36(5):427Google Scholar
  174. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70(1–2):1–20.  https://doi.org/10.1016/S0168-3659(00)00339-4CrossRefGoogle Scholar
  175. Storm DR, Rosenthal KS, Swanson PE (1977) Polymyxin and related peptide antibiotics. Annu Rev Biochem 46(1):723–763.  https://doi.org/10.1146/annurev.bi.46.070177.003451PubMedCrossRefPubMedCentralGoogle Scholar
  176. Su Y, Fu Z, Zhang J, Wang W, Wang H, Wang Y, Zhang Q (2008) Microencapsulation of Radix salvia miltiorrhiza nanoparticles by spray-drying. Powder Technol 184(1):114–121.  https://doi.org/10.1016/j.powtec.2007.08.014CrossRefGoogle Scholar
  177. Sun D, Li N, Zhang W, Zhao Z, Mou Z, Huang D, Liu J, Wang W (2016) Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease. Colloids Surf B: Biointerfaces 148:116–129.  https://doi.org/10.1016/j.colsurfb.2016.08.052PubMedCrossRefPubMedCentralGoogle Scholar
  178. Surendiran A, Sandhiya S, Pradhan S, Adithan C (2009) Novel applications of nanotechnology in medicine. Indian J Med Res 130(6):689–701PubMedPubMedCentralGoogle Scholar
  179. Sutton D, Nasongkla N, Blanco E, Gao J (2007) Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 24(6):1029–1046.  https://doi.org/10.1007/s11095-006-9223-yPubMedCrossRefPubMedCentralGoogle Scholar
  180. Takagaki A, Nanjo F (2009) Metabolism of (−)-epigallocatechin gallate by rat intestinal flora. J Agric Food Chem 58(2):1313–1321.  https://doi.org/10.1021/jf903375sCrossRefGoogle Scholar
  181. Tan Q, Liu W, Guo C, Zhai G (2011) Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomedicine 6:1621.  https://doi.org/10.2147/IJN.S22411PubMedCrossRefPubMedCentralGoogle Scholar
  182. Taylor E, Webster TJ (2011) Reducing infections through nanotechnology and nanoparticles. Int J Nanomedicine 6:1463.  https://doi.org/10.2147/IJN.S22021PubMedCrossRefPubMedCentralGoogle Scholar
  183. Tsai M-J, Huang Y-B, Fang J-W, Fu Y-S, Wu P-C (2015a) Preparation and characterization of naringenin-loaded elastic liposomes for topical application. PLoS One 10(7):e0131026.  https://doi.org/10.1371/journal.pone.0131026PubMedCrossRefPubMedCentralGoogle Scholar
  184. Tsai M-J, Huang Y-B, Fang J-W, Fu Y-S, Wu P-C (2015b) Preparation and evaluation of submicron-carriers for naringenin topical application. Int J Pharm 481(1–2):84–90.  https://doi.org/10.1016/j.ijpharm.2015.01.034PubMedCrossRefPubMedCentralGoogle Scholar
  185. Tubesha Z, Bakar ZA, Ismail M (2013) Characterization and stability evaluation of thymoquinone nanoemulsions prepared by high-pressure homogenization. J Nanomater 2013:126.  https://doi.org/10.1155/2013/453290CrossRefGoogle Scholar
  186. Uchegbu IF, Vyas SP (1998) Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 172(1–2):33–70.  https://doi.org/10.1016/S0378-5173(98)00169-0CrossRefGoogle Scholar
  187. Vadiei K, Perez-Soler R, Lopez-Berestein G, Luke DR (1989) Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine. Int J Pharm 57(2):125–131.  https://doi.org/10.1016/0378-5173(89)90300-1CrossRefGoogle Scholar
  188. Valenzuela A, Garrido A (1994) Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 27:105–105PubMedPubMedCentralGoogle Scholar
  189. Virmani R, Farb A, Guagliumi G, Kolodgie FD (2004) Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 15(6):313–318PubMedCrossRefGoogle Scholar
  190. Viswanathan V, Pharande R, Bannalikar A, Gupta P, Gupta U, Mukne A (2019) Inhalable liposomes of Glycyrrhiza glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo pharmacodynamic studies. Drug Dev Ind Pharm 45(1):11–20.  https://doi.org/10.1080/03639045.2018.1513025PubMedCrossRefPubMedCentralGoogle Scholar
  191. Von Nussbaum F, Brands M, Hinzen B, Weigand S, Häbich D (2006) Antibacterial natural products in medicinal chemistry—exodus or revival? Angew Chem Int Ed 45(31):5072–5129.  https://doi.org/10.1002/anie.200600350CrossRefGoogle Scholar
  192. Walunj M, Doppalapudi S, Bulbake U, Khan W (2019) Preparation, characterization and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. J Liposome Res (Just-Accepted):1–25.  https://doi.org/10.1080/08982104.2019.1593449
  193. Wang L, Zhao X, Zu Y, Wu W, Li Y, Zu C, Zhang Y (2016) Enhanced dissolution rate and oral bioavailability of ginkgo biloba extract by preparing nanoparticles via emulsion solvent evaporation combined with freeze drying (ESE-FR). RSC Adv 6(81):77346–77357.  https://doi.org/10.1039/C6RA14771BCrossRefGoogle Scholar
  194. Wang L, Zhao X, Yang F, Wu W, Liu Y, Wang L, Wang L, Wang Z (2019) Enhanced bioaccessibility in vitro and bioavailability of Ginkgo biloba extract nanoparticles prepared by liquid anti-solvent precipitation. Int J Food Sci Technol.  https://doi.org/10.1111/ijfs.14141
  195. Want MY, Islamuddin M, Chouhan G, Ozbak HA, Hemeg HA, Dasgupta AK, Chattopadhyay AP, Afrin F (2015) Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis. Colloids Surf B: Biointerfaces 130:215–221.  https://doi.org/10.1016/j.colsurfb.2015.04.013PubMedCrossRefPubMedCentralGoogle Scholar
  196. Waranuch N, Ramachandran C, Weiner ND (1998) Controlled topical delivery of cyclosporin-A from nonionic liposomal formulations: mechanistic aspects. J Liposome Res 8(2):225–238.  https://doi.org/10.3109/08982109809035528CrossRefGoogle Scholar
  197. Watkins R, Wu L, Zhang C, Davis RM, Xu B (2015) Natural product-based nanomedicine: recent advances and issues. Int J Nanomedicine 10:6055.  https://doi.org/10.2147/IJN.S92162PubMedCrossRefPubMedCentralGoogle Scholar
  198. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58(5):492–497.  https://doi.org/10.1016/0009-9236(95)90168-XPubMedCrossRefPubMedCentralGoogle Scholar
  199. Wu T-H, Yen F-L, Lin L-T, Tsai T-R, Lin C-C, Cham T-M (2008) Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 346(1–2):160–168.  https://doi.org/10.1016/j.ijpharm.2007.06.036PubMedCrossRefPubMedCentralGoogle Scholar
  200. Xie D, Xu Y, Jing W, Juxiang Z, Hailun L, Yu H, Zheng D-H, Lin Y-T (2017) Berberine nanoparticles protects tubular epithelial cells from renal ischemia-reperfusion injury. Oncotarget 8(15):24154.  https://doi.org/10.18632/oncotarget.16530PubMedCrossRefPubMedCentralGoogle Scholar
  201. Xu H, Yuan X-D, Shen B-D, Han J, Lv Q-Y, Dai L, Lin M-G, Yu C, Bai J-X, Yuan H-L (2014) Development of poly (N-isopropylacrylamide)/alginate copolymer hydrogel-grafted fabrics embedding of berberine nanosuspension for the infected wound treatment. J Biomater Appl 28(9):1376–1385.  https://doi.org/10.1177/0885328213509503PubMedCrossRefPubMedCentralGoogle Scholar
  202. Xue M, Yang M-X, Zhang W, Li X-M, Gao D-H, Ou Z-M, Li Z-P, Liu S-h, Li X-j, Yang S-Y (2013) Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine 8:4677.  https://doi.org/10.2147/IJN.S51262PubMedCrossRefPubMedCentralGoogle Scholar
  203. Yalkowsky SH (1999) Solubility and solubilization in aqueous media, vol 3. American Chemical Society, Washington, DCGoogle Scholar
  204. Yen F-L, Wu T-H, Lin L-T, Lin C-C (2007) Hepatoprotective and antioxidant effects of Cuscuta chinensis against acetaminophen-induced hepatotoxicity in rats. J Ethnopharmacol 111(1):123–128.  https://doi.org/10.1016/j.jep.2006.11.003PubMedCrossRefPubMedCentralGoogle Scholar
  205. Yen F-L, Wu T-H, Lin L-T, Cham T-M, Lin C-C (2008) Nanoparticles formulation of Cuscuta chinensis prevents acetaminophen-induced hepatotoxicity in rats. Food Chem Toxicol 46(5):1771–1777.  https://doi.org/10.1016/j.fct.2008.01.021PubMedCrossRefPubMedCentralGoogle Scholar
  206. Yen F-L, Wu T-H, Lin L-T, Cham T-M, Lin C-C (2009) Naringenin-loaded nanoparticles improve the physicochemical properties and the hepatoprotective effects of naringenin in orally-administered rats with CCl 4-induced acute liver failure. Pharm Res 26(4):893–902.  https://doi.org/10.1007/s11095-008-9791-0PubMedCrossRefPubMedCentralGoogle Scholar
  207. Yingchao L, Lei D, Ai J, Xinming C, Hui X (2007) Preparation and anti-fibrotic effects of solid lipid nanoparticles loaded with silibinin [J]. J Xi’an Jiaotong Univ (Med Sci) 5Google Scholar
  208. You-you T, Mu-Yun N, Yu-Rong Z, Lan-Na L, Shu-Lian C, Mu-Qun Z, Xiu-Zhen W, Zheng J, Xiao-Tian L (1982) Studies on the constituents of Artemisia annua Part II. Planta Med 44(03):143–145.  https://doi.org/10.1055/s-2007-971424PubMedCrossRefPubMedCentralGoogle Scholar
  209. Yuan X-B, Yuan Y-B, Jiang W, Liu J, Tian E-J, Shun H-M, Huang D-H, Yuan X-Y, Li H, Sheng J (2008) Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 349(1–2):241–248.  https://doi.org/10.1016/j.ijpharm.2007.07.045PubMedCrossRefPubMedCentralGoogle Scholar
  210. Yuan H, Ma Q, Ye L, Piao G (2016) The traditional medicine and modern medicine from natural products. Molecules 21(5):559.  https://doi.org/10.3390/molecules21050559PubMedCrossRefPubMedCentralGoogle Scholar
  211. Zakeri-Milani P, Loveymi BD, Jelvehgari M, Valizadeh H (2013) The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B: Biointerfaces 103:174–181.  https://doi.org/10.1016/j.colsurfb.2012.10.021PubMedCrossRefPubMedCentralGoogle Scholar
  212. Zaveri NT (2006) Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 78(18):2073–2080.  https://doi.org/10.1016/j.lfs.2005.12.006PubMedCrossRefPubMedCentralGoogle Scholar
  213. Zhang J, Liu J, Li X, Jasti B (2007) Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv 14(6):381–387.  https://doi.org/10.1080/10717540701203034PubMedCrossRefPubMedCentralGoogle Scholar
  214. Zhang J, Nie S, Wang S (2013a) Nanoencapsulation enhances epigallocatechin-3-gallate stability and its antiatherogenic bioactivities in macrophages. J Agric Food Chem 61(38):9200–9209.  https://doi.org/10.1021/jf4023004PubMedCrossRefPubMedCentralGoogle Scholar
  215. Zhang P, Lin R, Yang G, Zhang J, Zhou L, Liu T (2013b) Solubility of naringenin in ethanol and water mixtures. J Chem Eng Data 58(9):2402–2404.  https://doi.org/10.1021/je4000718CrossRefGoogle Scholar
  216. Zhang X-P, Le Y, Wang J-X, Zhao H, Chen J-F (2013c) Resveratrol nanodispersion with high stability and dissolution rate. LWT-Food Sci Technol 50(2):622–628.  https://doi.org/10.1016/j.lwt.2012.07.041CrossRefGoogle Scholar
  217. Zhang J, Zhou X, Yu Q, Yang L, Sun D, Zhou Y, Liu J (2014) Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity. ACS Appl Mater Interfaces 6(11):8475–8487.  https://doi.org/10.1021/am501341uPubMedCrossRefPubMedCentralGoogle Scholar
  218. Zhang H, Hou L, Jiao X, Ji Y, Zhu X, Zhang Z (2015a) Transferrin-mediated fullerenes nanoparticles as Fe2+−dependent drug vehicles for synergistic anti-tumor efficacy. Biomaterials 37:353–366.  https://doi.org/10.1016/j.biomaterials.2014.10.031PubMedCrossRefPubMedCentralGoogle Scholar
  219. Zhang H, Ji Y, Chen Q, Jiao X, Hou L, Zhu X, Zhang Z (2015b) Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles. J Drug Target 23(6):552–567.  https://doi.org/10.3109/1061186X.2015.1016437PubMedCrossRefPubMedCentralGoogle Scholar
  220. Zhang J, Nie S, Hossen MN, Sun M, Martinez-Zaguilan R, Sennoune S, Wang S (2015c) Anti-atherogenic effects of lesion-targeted epigallocatechin gallate (EGCG)-loaded nanoparticles. FASEB J 29(1_supplement):271.3Google Scholar
  221. Zhou Y, S-q L, Peng H, Yu L, He B, Zhao Q (2015) In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis. Int Immunopharmacol 28(1):34–43.  https://doi.org/10.1016/j.intimp.2015.05.014PubMedCrossRefPubMedCentralGoogle Scholar
  222. Zhu QY, Zhang A, Tsang D, Huang Y, Chen Z-Y (1997) Stability of green tea catechins. J Agric Food Chem 45(12):4624–4628.  https://doi.org/10.1021/jf9706080CrossRefGoogle Scholar
  223. Zimmerman JJ, Ferron GM, Lim HK, Parker V (1999) The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 39(11):1155–1161.  https://doi.org/10.1177/009127009903901107PubMedCrossRefPubMedCentralGoogle Scholar
  224. Zou Q, Li Y, Zhang L, Zuo Y, Li J, Li J (2009a) Antibiotic delivery system using nano-hydroxyapatite/chitosan bone cement consisting of berberine. J Biomed Mater Res A 89(4):1108–1117.  https://doi.org/10.1002/jbm.a.32199PubMedCrossRefPubMedCentralGoogle Scholar
  225. Zou W, Cao G, Xi Y, Zhang N (2009b) New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv 16(1):15–23.  https://doi.org/10.1080/10717540802481307PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PharmaceuticsNational Institute of Pharmaceutical Education & Research (NIPER)HyderabadIndia

Personalised recommendations